Get the Stockscreener App
6.24
0.97%
0.06
After Hours:
6.30
0.06
+0.96%
Dogwood Therapeutics Inc stock is traded at $6.24, with a volume of 28,676.
It is up +0.97% in the last 24 hours and up +27.61% over the past month.
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
See More
Previous Close:
$6.18
Open:
$6.18
24h Volume:
28,676
Relative Volume:
0.04
Market Cap:
$11.93M
Revenue:
-
Net Income/Loss:
$-5.73M
P/E Ratio:
-0.9527
EPS:
-6.55
Net Cash Flow:
$-4.13M
1W Performance:
-7.69%
1M Performance:
+27.61%
6M Performance:
+108.00%
1Y Performance:
+38.98%
1-Day Range:
$5.81
$6.4679
1-Week Range:
$5.33
$6.91
52-Week Range:
$1.62
$29.28
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Name
Dogwood Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Compare DWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
6.24 | 14.17M | 0 | -5.73M | -4.13M | -6.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Dogwood Therapeutics Inc Stock (DWTX) Latest News
What machine learning models say about Dogwood Therapeutics Inc.Dollar Strength & Weekly Setup with ROI Potential - newser.com
How sentiment analysis helps forecast Dogwood Therapeutics Inc.July 2025 Action & Pattern Based Trade Signal System - newser.com
Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025 - ACCESS Newswire
What to do if you’re stuck in Dogwood Therapeutics Inc.Portfolio Gains Report & Community Driven Trade Alerts - newser.com
Is Dogwood Therapeutics Inc. stock trading at a premium valuationQuarterly Portfolio Report & Stepwise Trade Signal Implementation - newser.com
Volume spikes in Dogwood Therapeutics Inc. stock – what they meanJuly 2025 Trends & Precise Trade Entry Recommendations - newser.com
Does Dogwood Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Big Picture & Accurate Intraday Trading Signals - newser.com
Will Dogwood Therapeutics Inc. stock keep outperforming rivalsWeekly Trading Summary & Consistent Return Investment Signals - newser.com
Will Dogwood Therapeutics Inc. stock reach all time highs in 20252025 Investor Takeaways & Safe Investment Capital Preservation Plans - newser.com
DWTX: Licenses SP16 for Treatment of Cancer Related Pain - Smartkarma
Will Dogwood Therapeutics Inc. stock benefit from sector rotationRisk Management & Weekly Watchlist for Consistent Profits - newser.com
Using RSI to spot recovery in Dogwood Therapeutics Inc.2025 Trading Volume Trends & Daily Growth Stock Tips - newser.com
Chart overlay techniques for tracking Dogwood Therapeutics Inc.Trend Reversal & Verified Technical Signals - newser.com
Statistical indicators supporting Dogwood Therapeutics Inc.’s strengthMarket Volume Summary & Weekly High Conviction Ideas - newser.com
Full technical analysis of Dogwood Therapeutics Inc. stockMarket Activity Recap & Verified Entry Point Signals - newser.com
Dogwood Therapeutics Announces Business Combination Plans - TipRanks
Dogwood to present Halneuron pain management research at summit By Investing.com - Investing.com Nigeria
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit - ACCESS Newswire
25 US Sites — Dogwood to Present Halneuron Pain Program at Pain Therapeutics Summit Oct 14 - Stock Titan
Will Dogwood Therapeutics Inc. price bounce be sustainableTrend Reversal & High Accuracy Buy Signal Tips - newser.com
Detecting price anomalies in Dogwood Therapeutics Inc. with AIWeekly Trend Summary & AI Driven Price Predictions - newser.com
What data driven models say about Dogwood Therapeutics Inc.’s futurePortfolio Performance Report & Reliable Entry Point Trade Alerts - newser.com
Is this a good reentry point in Dogwood Therapeutics Inc.2025 Institutional Moves & Real-Time Stock Movement Alerts - newser.com
How high can Dogwood Therapeutics Inc. stock goJuly 2025 Sentiment & Expert Curated Trade Ideas - newser.com
Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug - MSN
Dogwood Therapeutics files to sell 28.04M shares of common stock for holders - MSN
Maxim Group Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
H.C. Wainwright Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Raises Target Price to $12 - 富途牛牛
Dogwood Therapeutics (NASDAQ:DWTX) Given New $12.00 Price Target at HC Wainwright - Defense World
Dogwood Therapeutics stock price target raised to $12 from $10 at H.C. Wainwright - Investing.com
HC Wainwright & Co. Maintains Dogwood Therapeutics (DWTX) Buy Recommendation - Nasdaq
Dogwood Therapeutics (DWTX) Price Target Raised by HC Wainwright - GuruFocus
Dogwood Therapeutics Inc Stock (DWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):